west china medical publishers
Keyword
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Keyword "药物临床试验" 9 results
  • 如何做好药物临床试验机构资格认定申报的药物临床试验质量管理规范培训工作

    做好药物临床试验质量管理规范(GCP)培训工作是成功申报药物临床试验机构的关键。把GCP培训工作的重要性上升到认识层面,并积极行动,通过建立组织机构、配备专人负责培训,制定培训制度、方案,建立请假制度,开展形式多样的培训及建立培训档案等一系列的措施,从而保证培训效果,为顺利接受现场资格认定检查奠定了坚实基础。

    Release date:2021-06-23 07:35 Export PDF Favorites Scan
  • Clinical Trial Registration System and Evidence-Based Medicine

    This article briefly introduces the management of clinical trials of investigational new drugs, hospital-made preparations, post-marketing drugs and other types of clinical trials. The WHO International Clinical Trial Register Platform (WHO ICTRP), Chinese Clinical Trial Register (ChiCTR) and Chinese Clinical Trial Registration and Publishing Collaboration (ChiCTRPC) are also described. People conducting trials are advised to apply the basic philosophy of evidence-based medicine in their implementation, which is considered to be one of the guarantees of the validity of clinical trials.

    Release date:2016-09-07 02:15 Export PDF Favorites Scan
  • Adverse Drug Reaction of Compound Prescription of Huangyaozi (Dioscorea Bulbifera L.) in Clinical Trial and Its Management

    In phase II clinical trial of Compound Prescription of Huangyaozi (Dioscorea bulbifera L.), 7 cases out of 37 developed (18.92%) impairment of liver function. As a result, the ethic committee required researchers to report all data of safety of the drug and have all subjects rechecked about their liver function so as to provided reasonable evidence for the scientifical evaluation of the relationship between the drug and the adverse event and the succedent suspending of the clinical trial.

    Release date:2016-09-07 02:27 Export PDF Favorites Scan
  • 浅谈筹备申报药物临床试验机构资格认定的关键环节

    我国对开展药物临床试验的医疗机构实施准入制度。现对药物临床试验组织机构建设、药物临床试验质量管理规范(GCP)培训、材料组织3个环节的做法进行阐述,体现其在筹备申报药物临床试验机构资格认定工作中的关键作用。

    Release date:2016-09-07 02:33 Export PDF Favorites Scan
  • Obligation and Experience of Clinical Research Coordinator in Good Clinical Practice

    目前临床研究协调员(CRC)在完成高质量的临床试验中所扮演的角色越来越受到国内药物临床试验机构及药物申办者的广泛关注。作为临床试验过程中重要的一员,CRC承担着协调及管理临床试验项目的任务,具有“项目管理助手、后勤保障支持”的特点。四川大学华西医院国家药物临床试验机构在中医专业新药临床试验过程中,尝试配备CRC并在实际工作中取得了一定成效,同时也积累了实践经验。现就该机构中医专业新药临床试验过程中,CRC的运行机制和具体工作职责进行简要介绍,为各药物临床试验机构的建设和管理、药物临床试验的质量和整体水平的提高提供参考。

    Release date:2016-09-08 09:16 Export PDF Favorites Scan
  • 药物临床试验中的几个重要环节

    我国对新药临床研究有严格的审批制度。临床试验以前,需要一系列有关药学、药效、毒理、动物药代动力学等试验结果和文献资料为药物进入临床研究提供充分的理由和依据,保证进入临床试验时受试者得到最大的效益,并将可能遇到的风险降到最低限度,最大程度保护受试者的权益。安全和健康必须高于对科学和社会利益的考虑,因此规范的临床试验尤为重要。这就要求临床试验的各个环节都必须按照标准操作规程进行,且在科学与伦理道德两方面都合格,既要保护受试者的权益,又要保证其安全。

    Release date: Export PDF Favorites Scan
  • Evaluation and thinking of simulation effect of placebo on new drug clinical trials of traditional Chinese medicines

    Objectives To discuss the methodology of evaluation of traditional Chinese medicine (TCM) placebo simulation effects and the problems of blind implementation and so as to improve the quality of double-blind clinical trials of TCM. Methods Focusing on case of placebo preparation of TCM investigational new drug, simulation effects of the placebo were evaluated in terms of shape, color, taste and smell. The possibility of placebo be a drug and the similarity between placebo and drug were tested. Results There was no significant difference between placebo and investigational new drug to be judged as a drug (P>0.05). As for the similarity between placebo and drug, there was no significantly difference of the shape (P>0.05), for which the similarity was 100%. The color, taste and smell were significant different between placebo and drug (P<0.05), for which the similarity were 50%, 10% and 15% respectively. Conclusions It is very difficult to simulate TCM based on its certain color, taste or smell. Therefore, the subjects and the investigators’ compliance should be kept to avoid breaking the blind intentionally in the process of the trial and the influence of unblinding should be estimated at the end of the trial.

    Release date:2018-11-16 04:17 Export PDF Favorites Scan
  • Discussion of the mode of quality control in drug clinical trial involving introduction of nosocomial clinical research coordinator

    Establishing and improving the quality control system of drug clinical trial institutions is the key to ensure the quality of clinical trial. In recent years, the number of drug clinical trial has been continuously improved, and the quality control requirements have been continuously improved. However, in clinical work, the workload of medical staff is heavy, and the energy devoted to clinical trial is limited. Clinical research coordinator (CRC), as a participant and coordinator of clinical trial, has carried out transactional work related to non-medical judgment under the authorization and guidance of researchers, and has undertaken any specific work in clinical trial. Based on the quality control management experience of nosocomial CRC and hospital drug clinical trial institutions in West China Hospital of Sichuan University, this paper discusses the mode of nosocomial CRC participating in clinical trial quality control. By participating in the quality control of clinical trial, the nosocomial CRC has improved the quality control efficiency, enriched the quality control team and improved the overall level of CRC. This model enriches the quality control system of drug clinical trial.

    Release date: Export PDF Favorites Scan
  • Umbrella trial for clinical trial design of oncology drugs

    The umbrella trial has received increasing attention in the design of clinical trials for oncology drugs in recent years. This trial design categorizes a single disease into multiple sub-types based on predictive biomarkers or other predictive factors, and simultaneously evaluates the efficacy of multiple targeted therapies. When compared with the traditional drug development model of phase Ⅰ, phaseⅡ, and phase Ⅲ randomized controlled trials, umbrella trials are a more scientifically rigorous trial design that can speed up drug evaluation to address the conflict between numerous untested drugs and diseases with a lack of effective treatment options. This article will focus on the concept, main characteristics, eligibility criteria, design and statistical considerations, ethical considerations, and future directions of umbrella trials, with the aim of providing methodological guidance for the design of clinical trials for oncology drugs.

    Release date: Export PDF Favorites Scan
1 pages Previous 1 Next

Format

Content